Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, ...
Tag: Novo Nordisk A/S
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, Health Department agency says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.Brendan ...
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.Brendan ...
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Doximity at the New York Stock Exchange for their IPO, June 24, 2021.Source: NYSEIf the Covid era marked a boom ...
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March ...
The weight-loss drug boom has become one of the internet’s biggest scams
A production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in ...
FTC sues drug middlemen for allegedly inflating insulin prices
Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Subcommittee at the Rayburn House Office ...
Federal Trade Commission to sue drug middlemen over prices of medications including insulin, source says
Federal Trade Commission Chair Lina Khan testifies during a hearing of the House Appropriations Subcommittee on Financial Services and General ...
This ETF is trying to satisfy appetites for weight loss stocks
Tema ETFs has been capitalizing on the risk appetite for weight loss stocks.It is behind the GLP-1, Obesity & Cardiometabolic ...
This new weight loss drug ETF bets big on two of the industry’s leading players
A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs.Roundhill Investments' GLP-1 & Weight ...
